Genmab As Stock Analysis

Genmab Stock Analysis Notes

The book value of the company was currently reported as 577.54. The company has Price/Earnings To Growth (PEG) ratio of 1.14. Genmab AS had not issued any dividends in recent years. The entity had 5:1 split on the 1st of May 2018. Genmab AS develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. Genmab AS was founded in 1999 and is headquartered in Copenhagen, Denmark. Genmab AS is traded on NASDAQ Exchange in the United States. To learn more about Genmab AS call the company at 45 70 20 27 28 or check out https://www.genmab.com.

Genmab AS Investment Alerts

Genmab AS Upcoming and Recent Events

Genmab Largest EPS Surprises

View All Earnings Estimates

Genmab AS Environmental, Social, and Governance (ESG) Scores

Genmab AS Thematic Classifications

Genmab Stock Institutional Investors

Note, although Genmab AS's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Genmab Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 12.92 B.

Genmab Profitablity

The company has Profit Margin (PM) of 0.36 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.35 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.35.

Management Efficiency

Genmab AS has return on total asset (ROA) of 0.1091 % which means that it generated a profit of $0.1091 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2297 %, meaning that it created $0.2297 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.27. The current year's Return On Capital Employed is expected to grow to 0.17. At present, Genmab AS's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 18.9 B, whereas Other Current Assets are forecasted to decline to about 110.3 M.

Technical Drivers

As of the 19th of March, Genmab AS retains the Risk Adjusted Performance of (0.02), standard deviation of 2.72, and Market Risk Adjusted Performance of (0.11). Genmab AS technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.

Genmab AS Price Movement Analysis

Genmab AS Outstanding Bonds

Genmab AS Predictive Daily Indicators

Genmab AS Corporate Filings

Genmab AS Forecast Models

Genmab AS's time-series forecasting models are one of many Genmab AS's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Genmab AS's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Genmab AS prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Genmab shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Genmab AS. By using and applying Genmab Stock analysis, traders can create a robust methodology for identifying Genmab entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Genmab analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Genmab analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Genmab AS stock analysis indicators help investors evaluate how Genmab AS stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Genmab AS shares will generate the highest return on investment. By understating and applying Genmab AS stock analysis, traders can identify Genmab AS position entry and exit signals to maximize returns.

When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.